Quince Therapeutics, Inc. (IRLA): Cash & Equivalents
$5.81M
As of 2025-12-31
$115.98M
As of 2026-06-30
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $5.81M | -6.5% | 2026-04-10, Balance as of period end |
| 2024-12-31 | $6.21M | n/a | 2026-04-10, Balance as of period end |
| No annual figure between 2019-12-31 and 2024-12-31. | |||
| 2019-12-31 | $51.21M | +105.9% | 2020-03-16, Balance as of period end |
| 2018-12-31 | $24.87M | n/a | 2020-03-16, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Quince Therapeutics, Inc. (IRLA) | 2025-12-31 | $5.81M | -6.5% |
| aTYR PHARMA INC (ATYR) | 2025-12-31 | $10.74M | -2.8% |
| LeonaBio, Inc. (LONA) | 2025-12-31 | $69.28M | +43.0% |
| Surrozen, Inc. (SRZN) | 2025-12-31 | $89.25M | +158.2% |
| Aligos Therapeutics, Inc. (ALGS) | 2025-12-31 | $18.30M | -50.5% |
| Anavex Life Sciences Corp. (AVXL) | 2025-09-30 | $102.58M | -22.4% |
| Protalix BioTherapeutics, Inc. (PLX) | 2025-12-31 | $14.68M | -25.7% |
| Alpha Cognition Inc. (ACOG) | 2025-12-31 | $66.05M | +36.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $40.79M | -10.9% |
Compare IRLA, ATYR, LONA, SRZN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗